Gilead Sciences (GILD) Accumulated Expenses (2009 - 2022)

Gilead Sciences (GILD) has reported Accumulated Expenses for 14 consecutive years, with $3.9 billion the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Accumulated Expenses rose 2.22% year-over-year to $3.9 billion; the trailing twelve-month figure through Sep 2022 stood at $3.9 billion (up 2.22% YoY), and the FY2021 full-year result was $6.1 billion, up 41.72% from the prior year.
• Accumulated Expenses eased to $3.9 billion in Q3 2022 per GILD's latest filing, from $4.1 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.1 billion in Q4 2021 and bottomed at $2.3 billion in Q3 2018.
• Historically, Accumulated Expenses has averaged $3.4 billion across 5 years, with a median of $3.5 billion in 2022.
• The sharpest annual moves came in 2018 and 2020: Accumulated Expenses decreased 12.84% in 2018, then soared 48.69% in 2020.
• Over 5 years, Accumulated Expenses stood at $3.1 billion in 2018, then fell by 2.07% to $3.1 billion in 2019, then soared by 41.05% to $4.3 billion in 2020, then surged by 41.72% to $6.1 billion in 2021, then slumped by 37.1% to $3.9 billion in 2022.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.9 billion, $4.1 billion, and $3.5 billion for Q3 2022, Q2 2022, and Q1 2022 respectively.